Related stories
Apyx Medical 3Q 2026: Revenue $14.03M, EPS ($0.04) — 10-Q Summary
Apyx Medical's third-quarter sales rose 9.0% year over year, while its net loss narrowed. Growth in Surgical Aesthetics, led by AYON sales and higher international generator sales,
L impact | EARNINGS | Nov 05, 2026, 04:03 PM UTC
GENMAB 9M OPERATING PROFIT USD 986 MILLION
L impact | EARNINGS | Nov 05, 2026, 04:03 PM UTC
United Bancorp Reports Q3 EPS of $0.25
L impact | EARNINGS | Nov 05, 2026, 04:02 PM UTC
Genmab Reports Nine-Month 2026 Financial Results
Genmab released its interim report for the nine months ended September 30, 2026. The report highlights approval in Europe of TEPKINLY plus R(2) for second-line follicular lymphoma.
L impact | EARNINGS | Nov 05, 2026, 04:02 PM UTC
PodcastOne Issues Final Guidance After Record $31.5M First-Half Revenue
PodcastOne reported first-half revenue of $31.5 million and adjusted EBITDA of $3 million, up 76%.
M impact | EARNINGS | Nov 05, 2026, 04:01 PM UTC
Medanta Reports 60.2% EBITDA Growth, Approves Rs 997-Crore Hospital Project
Hospital chain posts 33.6 per cent revenue growth in Q2 FY27, with plans to add over 3,450 beds through six greenfield projectsMedanta reported a 33.6 per cent year-on-year increas
L impact | EARNINGS | Nov 05, 2026, 04:01 PM UTC